mRNA Vaccine for COVID-19 and Flu

Palo Alto (17 mi)

Age: 18 - 65

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: ModernaTX, Inc.

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.

Eligibility Criteria

This clinical trial is for adults aged between 50 and 65 who are in good health. The study aims to test a new vaccine targeting COVID-19 and the flu.

Inclusion Criteria

I am not pregnant and am using or willing to use effective birth control or abstain from activities that could lead to pregnancy.

Exclusion Criteria

I haven't taken immune-weakening drugs in the last 6 months.

I have been vaccinated against COVID-19 within the last 90 days.

I have a history of immune system problems or frequent severe infections.

I have taken high-dose steroids recently or might need them during the study.

Treatment Details

The trial is testing mRNA-1083, a combined vaccine for SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants will receive one intramuscular injection of the vaccine.

4Treatment groups

Experimental Treatment

Group I: Group 4: mRNA-1083 Lot DExperimental Treatment1 Intervention

Participants will receive mRNA-1083 Lot D as a single injection on Day 1.

Group II: Group 3: mRNA-1083 Lot CExperimental Treatment1 Intervention

Participants will receive mRNA-1083 Lot C as a single injection on Day 1.

Group III: Group 2: mRNA-1083 Lot BExperimental Treatment1 Intervention

Participants will receive mRNA-1083 Lot B as a single injection on Day 1.

Group IV: Group 1: mRNA-1083 Lot AExperimental Treatment1 Intervention

Participants will receive mRNA-1083 Lot A as a single injection on Day 1.